Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tagrisso for EGFR-mutated NSCLC with asymptomatic brain metastases
MOH_2017-11-19_001959Phase 2Not yet recruiting
- Sponsor
- פרופ' ניר פלד
- Start
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of osimertinib in non-small cell lung cancer (NSCLC) (3 cohorts), sponsored by פרופ' ניר פלד. Planned start Sep 2017; status: not yet recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on MOH_2017-11-19_001959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-11-19_001959.